Navigation Links
Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
Date:2/25/2009

SAN DIEGO and MONTREAL, Feb. 25 /PRNewswire/ -- Speid & Associates, an international regulatory and drug development consultancy firm today announced that it has entered into a partnership with Genizon BioSciences to increase success rates of new drug compounds using Genizon's proprietary genetic platform. In this challenging economic climate in which innovative pharmaceutical and biotechnology companies have to watch every dollar that is spent on drug development, the Genizon and Speid collaboration will help to increase the ultimate success of drug development programs. Genizon's predictive techniques will also enable Speid's clients to identify and eliminate compounds with relatively low chances of success earlier than if these techniques are not used.

"As we develop effective regulatory strategies for our clients' drug candidates, I am very pleased that Genizon will work alongside us at our clients' requests," said Lorna Speid, Ph.D., president of Speid & Associates. Dr. Speid added, "I anticipate that the Genizon technology and expertise will allow our clients to re-visit compounds that may have been placed on the 'back-burner', but which may hold promise as new medications."

"We believe that we can add significant value to Speid & Associates' clients through pharmacogenomic studies and analyses using our gene discovery platform and expertise. These enable invaluable insights into drug response, and therefore improve clinical trial outcomes," said Majid Belouchi, Ph.D., founder and chief scientific officer of Genizon. He added, "We use predictive biomarkers to identify patients who are more likely to respond to a given treatment. Consequently, the combination of Genizon's proprietary gene discovery platform and Speid's expertise in regulatory affairs will assure expeditious pathways to commercialization."

About Genizon BioSciences

Genizon BioSciences Inc. is a leader in genetic solutions. Genizon discovers genes, genetic biomarkers, biochemical pathways and drug targets that are involved in human disease susceptibility and drug response. These genetic insights allow the development of predictive diagnostics that facilitate personalized medicine. Working with a network of over 1,000 clinical investigators, Genizon has recruited over 47,000 subjects in 25 common diseases, which are analyzed in a unique, integrated high throughput facility that is compliant with GCP and GLP guidelines. Discoveries are translated into clinical practice through collaborative research with academic and clinical leaders. Genizon also provides high throughput, high quality SNP genotyping, genetic analysis, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

For more information visit: www.genizon.com

About Speid & Associates, Inc.

Speid & Associates, Inc. is a privately held regulatory affairs and drug development consultancy based in San Diego, California. Speid & Associates assists life science companies move new chemical entities to the finish line expeditiously by developing effective global regulatory strategies for the international pharmaceutical and biotechnology industries. Speid also conducts due diligence for investors and companies.

For more information visit: www.drugstomarket.com


'/>"/>
SOURCE Genizon BioSciences Inc.; Speid & Associates, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology:
(Date:8/15/2017)... LLC , a medical device company focused on improving the safety ... ISO 13485 Certification, the global standard for medical device quality management ... ... for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates our ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
Breaking Biology News(10 mins):